Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD Registry

Abstract

Background:

The wearable cardioverter-defibrillator is a treatment option for patients at temporarily high risk of sudden cardiac death or in whom implantation of a cardioverter-defibrillator is temporarily not possible.

Objectives:

The aim of this study was to provide real-world data on patients receiving this therapy in a nurse-based wearable cardioverter-defibrillator training programme.

Methods:

A registry including all patients prescribed with a wearable cardioverter-defibrillator in Austria between 2010 and 2016. Overall, 448 patients received a wearable cardioverter-defibrillator in 48 centres. Patients received structured nurse-based wearable cardioverter-defibrillator educational initial training followed by remote monitoring.

Results:

Main indications were: severe non-ischaemic cardiomyopathy (21%); recent myocardial infarction and percutaneous coronary intervention (20%); and stable coronary artery disease with percutaneous coronary intervention/coronary artery bypass grafting (14%). Eleven patients (2.5%) received 22 appropriate wearable cardioverter-defibrillator shocks. Two patients (0.4%) received three inappropriate shocks. The risk of sudden cardiac death varied between different aetiologies. Eight out of 11 (73%) patients received their first wearable cardioverter-defibrillator shock within 30 days. The main reasons for termination of the wearable cardioverter-defibrillator therapy were implantable cardioverter-defibrillator implantation (55.5%) and improvement of left ventricular ejection fraction to more than 35% (33%).

Conclusion:

The wearable cardioverter-defibrillator is an effective and safe treatment option in patients at either transiently elevated risk of ventricular tachycardia/ventricular fibrillation or mandated postponed implantable cardioverter-defibrillator implantation, with a 2.5% shock rate over a median 54 days wearable cardioverter-defibrillator treatment period. However, both the wearable cardioverter-defibrillator shock rate and implantable cardioverter-defibrillator implantation rate vary widely depending on the wearable cardioverter-defibrillator indication. Nurse-based wearable cardioverter-defibrillator training is associated with high patient adherence, with a median wearing duration per day of 23.5 (1–24) hours.

Keywords

Wearable defibrillator sudden cardiac death arrhythmia Lifevest ICD

Get full access to this article

View all access options for this article.

References

Rai

Agrawal

Role of risk stratification and genetics in sudden cardiac death. Can J Physiol Pharacol 2017; 95: 225–238.

Brignole

Auricchio

Baron-Esquivias

et al . 2013 Guidelines on cardiac pacing and cardiac resynchronization therapy. EuroHeart J 2013; 34: 2281–2329.

Ponikowski

Voors

Anker

et al . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. EuroHeart J 2016; 37: 2129–2220.

Priori

Blomström-Lundqvist

Mazzanti

et al . 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. EuroHeart J 2015; 16: 2793–2867.

Kutyifa

Moss

Klein

et al . Use of the wearable cardioverter defibrillator in high-risk cardiac patients. Data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015; 132: 1612–1619.

Chung

Szymkiewicz

Shao

et al . Aggregate national experience with the wearable cardioverter-defibrillator. Event rates, compliance, and survival. J Am Coll Cardiol 2010; 56: 194–203.

Feldmann

Klein

Tchou

et al . Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROD. Pacing Clin Electrophysiol 2004; 27: 4–9.

Zishiri

Williams

Cronin

et al . Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2013; 6: 117–128.

Epstein

Abraham

Bianco

et al . Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post myocardial infarction. J Am Coll Cardiol 2013; 62: 2000–2007.

10.

Shing

Wang

Jain

et al . Utility of the wearable cardioverter-defibrillator in patients with newly diagnosed cardiomyopathy: a decade-long single-center experience. J Am Coll Cardiol 2015; 66: 2607–2613.

11.

Reek

Burri

Roberts

et al . The wearable cardioverter-defibrillator: current technology and evolving indications. Europace 2017; 19: 335–345.

12.

Saltzberg

Szymkiewicz

Bianco

Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Cardiac Fail 2012; 18: 21–27.

13.

Wässnig

Günther

Quick

et al . Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 2016; 134: 635–643.

14.

Ellenbogen

Koneru

Sharma

et al . Benefit of the wearable cardioverter-defibrillator in protecting patients after implantable-cardioverter defibrillator explant. JACC EP 2017; 3: 243–250.

15.

Kindermann

Kandolf

et al . Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118: 639–648.

16.

Prochnau

Surber

Kuehnert

et al . Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction. Clin Res Cardiol 2010; 99: 129–131.

17.

Chung

The role of the wearable cardioverter defibrillator in clinical practice. Cardiol Clin 2014; 32: 253–270.

18.

Thune

Pehrson

Nielsen

et al . Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of implantable cardioverter defibrillators in patients with non-ischemic systolic heart failure on mortality (DANISH). Am Heart J 2016; 179: 136–141.

19.

Kadish

Dyer

Daubert

et al . Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathies. N Engl J Med 2004; 350: 2151–2158.

20.

Salehi

et al . The wearable cardioverter defibrillator in nonischemic cardiomyopathy: a US national database analysis. Can J Cardiol 2016; 32: 1247.

21.

Pouleur

Barkoudah

Uno

et al . Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation 2010; 122: 597–602.

22.

Klein

Meltendorf

Reek

et al . Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). Pacing Clin Electrophysiol 2010; 33: 353–367.

23.

Auricchio

Schloss

Kurita

et al . Low inappropriate shock rates in patients with single and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm 2015; 12: 926–936.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB